Medium: Pharmacy Benefit Managers – Providing Lower Prescription Costs for State Medicaid Programs Dealing with COVID-19 June 5, 2020 Given this growing challenge, pharmacy benefit managers (PBMs) have never been more essential. For both public programs and private insurance, PBMs
This practice, the HHS inspector general said, could harm patients, the government and taxpayers because people might take pricey drugs instead of cheaper ones.
Our collective will and intellects are being called upon to manage COVID-19, save lives, and restore our economy. During this public health emergency, it is crucial that every sector of our health care system step up to the challenge. And
Today, Thursday March 9, The Hill is hosting an important conversation titled: “Prescription for Change: Improving Competition to Lower Drug Prices,” featuring: David Schweikert (R-AZ), Member, Ways & Means Committee Tina Smith (D-MN), Member, Senate HELP Committee Lauren Aronson, Executive
Makers of brand-name drugs called out by the Trump administration for potentially stalling generic competition have hiked their prices by double-digit percentages since 2012 and cost Medicare and Medicaid nearly $12 billion in 2016, a Kaiser Health News analysis has
PhRMA was one of AAN’s biggest donors the previous year, giving it $6.1 million, federal regulatory findings show
Though drug makers continue to raise prices out of proportion to increases in value, PBMs are doing their job by keeping drug costs down
Even including discounts, however, the company’s net profit margin for 2017 was 34 percent, its highest since at least 2000, when it was half that high.
©2024 PCMA. All Rights Reserved.
